title: Hepatitis C transmission from viremic donors in hematopoietic stem cell transplant.
abstract: Transmission of hepatitis C virus (HCV) to recipients of hematopoietic stem cell transplant (HSCT) occurs frequently from HCV viremic donors and causes complications. Here, we report the outcomes of 3 cases from our 265 allogeneic HSCTs, whose donors had HCV infections. Successful prevention of HCV transmission was noted in 1 recipient by pretreatment of the donor with peginterferon/ribavirin to undetectable levels of HCV viremia before stem cell harvest. This case stressed the important role of effective antiviral therapy and HCV RNA seronegativity before cell harvest for prevention of HCV transmission in HSCT.
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Faculty of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
authors.forename: H-H
authors.initials: HH
authors.lastname: Hsiao
authors.forename: Y-C
authors.initials: YC
authors.lastname: Liu
authors.forename: H-C
authors.initials: HC
authors.lastname: Wang
authors.forename: C-H
authors.initials: CH
authors.lastname: Wu
authors.forename: S-F
authors.initials: SF
authors.lastname: Cho
authors.forename: J-F
authors.initials: JF
authors.lastname: Hsu
authors.forename: H-J
authors.initials: HJ
authors.lastname: Tsai
authors.forename: S Y
authors.initials: SY
authors.lastname: Hsiao
authors.forename: C-S
authors.initials: CS
authors.lastname: Chang
authors.forename: S-F
authors.initials: SF
authors.lastname: Lin
authors.forename: T-C
authors.initials: TC
authors.lastname: Liu
authors.forename: W-L
authors.initials: WL
authors.lastname: Chuang
authors.forename: M-L
authors.initials: ML
authors.lastname: Yu
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D016174:Hepacivirus / Q000302:isolation & purification; D006526:Hepatitis C / Q000188:drug therapy / Q000635:transmission* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D014019:Tissue Donors; D019562:Viral Load; D014766:Viremia
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a
keywords: HCV; HSCT; hematopoietic stem cell transplantation; hepatitis C virus; transmission prevention